Table 3.
Selected clinical studies on advanced-stage and relapsed/refractory NK/T-cell lymphomas
| Study (reference) | Disease | No. | Treatment | ORR | CR | OS | PFS/DFS |
|---|---|---|---|---|---|---|---|
| Phase II [67] | Newly diagnosed stage IV, relapsed/refractory | 38 | SMILE | 79% | 45% | 1-year: 55% | 1-year: 53% |
| Retrospective [68] | Newly diagnosed stage IV | 26 | SMILE | NR | 54% | 5-year: 47% | 4-year: 60% |
| Phase III [74] | Newly diagnosed, advanced stage | 21 | DDCP | 95% | 71% | 1-year: 90% | 1-year: 86% |
| 21 | SMILE | 67% | 29% | 1-year: 57% | 1-year: 38% | ||
| Phase II [75] | Newly diagnosed, advanced stage | 22 | IMP L-asp | 90% | 65% | 1-year: 76% | 1-year: 43% |
| Phase II [76] | Relapsed/refractory | 19 | AspaMetDex | 78% | 61% | 2-year: 40% | 2-year: 40% |
| Retrospective [68] | Relapsed/refractory | 44 | SMILE | 77% | 66% | 5-year: 52% | 4-year: 68% |
| Retrospective [77] | Relapsed/refractory | 13 | MEDA | 77% | 61% | 1-year: 69% | 1-year: 62% |
| Retrospective [84] | Relapsed/refractory | 7 | Pembrolizumab | 100% | 71% | NR | NR |
No. number of patients, ORR overall response rate, CR complete response, OS overall survival, PFS progression-free survival, DFS disease-free survival, SMILE dexamethasone, methotrexate, ifosfamide, L-asparaginase, etoposide, DDCP dexamethasone, gemcitabine, cisplatinum, pegasparaginase, IMP L-asp ifosfamide, methotrexate, etoposide, prednisolone, L-asparaginase, AspaMetDex L-asparaginase, methotrexate, dexamethasone, MEDA methotrexate, etoposide, dexamethasone, L-asparaginase